Last reviewed · How we verify
NCT02677376
Imaging Biomarkers to Validate Response in Enzalutamide-Treated mCRPC
trial testing 18F-Sodium Fluoride (NaF) in Prostatic Neoplasms in 7 participants. Completed in 3 January 2020.
30 March 2018
Quick facts
| Lead sponsor | University of Wisconsin, Madison |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 7 |
| Start date | 27 June 2016 |
| Primary completion | 30 March 2018 |
| Estimated completion | 3 January 2020 |
| Sites | 1 location across United States |
Drugs / interventions tested
- 18F-Sodium Fluoride (NaF) — full drug profile →
Conditions studied
- Prostatic Neoplasms — all drugs for Prostatic Neoplasms →
Sponsor
University of Wisconsin, Madison
Who can join
18 and older, male only, with Prostatic Neoplasms. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To determine the feasibility and success rate of tumor tissue procurement using molecular-image-directed biopsies of responding and non-responding osseous metastases, measured by NaF PET/CT, in patients with metastatic castrate-resistant prostate cancer.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Molecular image-directed biopsies: improving clinical biopsy selection in patients with multiple tumors.
Harmon SA, Tuite MJ, Jeraj R. · · 2016 · cited 4× · PMID 27694707 · DOI 10.1088/0031-9155/61/20/7282
Verify or expand the search:
- PubMed search for NCT02677376
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Prostatic Neoplasms
Currently open trials in the same condition.
- NCT07285057 — Diagnostic Utility of rhPSMA-7.3 (18F) PET/CT in Men With Prostate Cancer on Active Surveillance · Phase 2 · recruiting
- NCT07319871 — A Study of Pasritamig (JNJ-78278343) in Combination With JNJ-86974680 for Treatment of Prostate Cancer · Phase 1 · recruiting
- NCT07335224 — Men With Prostate Cancer: Optimizing Wellness by Enhanced Relief From Hot Flashes With Acupuncture · NA · recruiting
- NCT07451002 — A Study to Assess Adherence to Apalutamide in Metastatic Hormone-Sensitive Prostate Cancer Participants in France · recruiting
- NCT06547398 — Prostate Adaptive Radiation Therapy · NA · recruiting
Other University of Wisconsin, Madison trials
Trials by the same sponsor.
- NCT07440004 — Testing a Digital Mindfulness Program to Support People Experiencing Suicidal Thoughts · Phase 1 · recruiting
- NCT07278466 — The COMParing App Support Strategies Study · NA · recruiting
- NCT07475104 — Redesigning Surgical Care for Patients in Wisconsin · NA · enrolling by invitation
- NCT07470723 — The ORIGIN-FH Study · NA · recruiting
- NCT06975657 — Well-being Skills for Reentry · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02677376 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Wisconsin, Madison
- Last refreshed: 26 February 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02677376.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing